title: Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.
authors.affiliation: Bharti Hospital, Karnal, Haryana, India.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kalra
authors.affiliation: Department of Medicine, Government Medical College & Hospital, Sector 32, Chandigarh, India yash_deep_gupta@yahoo.co.in.
authors.forename: Yashdeep
authors.initials: Y
authors.lastname: Gupta
authors.affiliation: Excel Hospitals, Guwahati, Assam, India.
authors.forename: Manash P
authors.initials: MP
authors.lastname: Baruah
authors.affiliation: Department of Neurology, Postgraduate Institute of Medical Education & Research, Chandigarh, India.
authors.forename: Anu
authors.initials: A
authors.lastname: Gupta
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000453:epidemiology*; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D051437:Renal Insufficiency / Q000188:drug therapy*
chemical_list: D004151:Dipeptides; D000218:Adamantane